Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Parameters of anxiety in children with cancer vary according to instrument used

06 Feb 2019

The severity, patterns over time and predictors of anxiety in children and adolescents undergoing chemotherapy or haematopoietic stem cell transplantation (HSCT) change with different instruments used, a new study has found.

Seventy-seven paediatric patients (median age 13.2 years; 35.1 percent female) participated, in whom self-reported anxiety at chemotherapy or HSCT initiation was measured using three instruments: the Paediatric Quality of Life Inventory (PedsQL) 3.0 Acute Cancer Module, the Paediatric Patient-Reported Outcomes Measurement Information System (PROMIS) Paediatric Short-Form (SF) and the Multidimensional Anxiety Scale for Children (MASC).

At baseline, the percentage of participants who had severe anxiety ranged from 13.0–28.6 percent and varied according to the instrument used. When the PedsQL (procedural anxiety subscale: p=0.037) and PROMIS (p=0.013) instruments were used, significant improvements in anxiety were observed. No such change was recorded by the MASC.

There also seemed to be a variation among instruments regarding predictive factors. Univariate linear regression analysis showed that in the PedsQL instrument, age was a significant risk factor for anxiety, such that children aged 16–18 years reported more worries than those aged 8–11 years (p=0.036).

In comparison, the MASC instrument reported that lower annual household income was also a significant risk factor for anxiety in the participants (p=0.028).

The present findings highlight the heterogeneous nature of childhood anxiety and the need for careful consideration when choosing a measurement instrument, said researchers. Future studies about anxiety in paediatric cancer should focus on a particular facet of anxiety.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.